CA2597065C - Compositions and methods related to soluble g-protein coupled receptors (sgpcrs) - Google Patents

Compositions and methods related to soluble g-protein coupled receptors (sgpcrs) Download PDF

Info

Publication number
CA2597065C
CA2597065C CA2597065A CA2597065A CA2597065C CA 2597065 C CA2597065 C CA 2597065C CA 2597065 A CA2597065 A CA 2597065A CA 2597065 A CA2597065 A CA 2597065A CA 2597065 C CA2597065 C CA 2597065C
Authority
CA
Canada
Prior art keywords
soluble
compositions
methods related
protein coupled
coupled receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2597065A
Other languages
English (en)
French (fr)
Other versions
CA2597065A1 (en
Inventor
Alon Chen
Marilyn Perrin
Wylie Vale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Development Foundation
Original Assignee
Research Development Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Development Foundation filed Critical Research Development Foundation
Publication of CA2597065A1 publication Critical patent/CA2597065A1/en
Application granted granted Critical
Publication of CA2597065C publication Critical patent/CA2597065C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
CA2597065A 2005-02-08 2006-02-08 Compositions and methods related to soluble g-protein coupled receptors (sgpcrs) Expired - Fee Related CA2597065C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65086605P 2005-02-08 2005-02-08
US60/650,866 2005-02-08
PCT/US2006/004321 WO2006086402A2 (en) 2005-02-08 2006-02-08 Compositions and methods related to soluble g-protein coupled receptors(sgpcrs)

Publications (2)

Publication Number Publication Date
CA2597065A1 CA2597065A1 (en) 2006-08-17
CA2597065C true CA2597065C (en) 2014-10-14

Family

ID=36793648

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2597065A Expired - Fee Related CA2597065C (en) 2005-02-08 2006-02-08 Compositions and methods related to soluble g-protein coupled receptors (sgpcrs)

Country Status (11)

Country Link
US (2) US7507794B2 (https=)
EP (1) EP1885746B1 (https=)
JP (1) JP4859248B2 (https=)
KR (1) KR20070112155A (https=)
CN (1) CN101137668B (https=)
AT (1) ATE540970T1 (https=)
AU (1) AU2006212813B2 (https=)
CA (1) CA2597065C (https=)
DK (1) DK1885746T3 (https=)
RU (1) RU2423378C2 (https=)
WO (1) WO2006086402A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7815905B2 (en) * 2006-01-27 2010-10-19 Research Development Foundation Methods of increasing insulin sensitivity or decreasing insulin secretion by administering corticotropin releasing factor receptor-2 inhibitors
EP2190533A2 (en) * 2007-09-11 2010-06-02 Mondobiotech Laboratories AG Use of a peptide as a therapeutic agent
US20100204113A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Use of stresscopin-related peptide as a therapeutic agent
KR20100056507A (ko) * 2007-09-11 2010-05-27 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드 ｐｒｏ－ｇｌｙ－ｔｈｒ－ｃｙｓ－ｇｌｕ－ｉｌｅ－ｃｙｓ－ａｌａ－ｔｙｒ－ａｌａ－ａｌａ－ｃｙｓ－ｔｈｒ－ｇｌｙ－ｃｙｓ의 용도
WO2009046874A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Therapeutic combination of trh-potentiating peptide and stresscopin
WO2011025905A1 (en) 2009-08-28 2011-03-03 Research Development Foundation Urocortin 2 analogs and uses thereof
WO2011062935A1 (en) * 2009-11-17 2011-05-26 The Regents Of The University Of California Compositions and assay systems for intracellular processes
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
US9981017B2 (en) 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
SG10201701547VA (en) * 2011-02-23 2017-03-30 Massachusetts Inst Technology Water soluble membrane proteins and methods for the preparation and use thereof
CN108310396B (zh) 2012-02-14 2022-07-15 加利福尼亚大学董事会 用于心血管疾病和其它病况的旁分泌基因的全身性递送和受调节的表达
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
WO2018132768A1 (en) * 2017-01-13 2018-07-19 Sanna Pietro P Methods and compositions for treating hpa hyperactivity
US10995361B2 (en) 2017-01-23 2021-05-04 Massachusetts Institute Of Technology Multiplexed signal amplified FISH via splinted ligation amplification and sequencing
WO2018157074A1 (en) 2017-02-24 2018-08-30 Massachusetts Institute Of Technology Methods for diagnosing neoplastic lesions
WO2018157048A1 (en) 2017-02-24 2018-08-30 Massachusetts Institute Of Technology Methods for examining podocyte foot processes in human renal samples using conventional optical microscopy
US11180804B2 (en) 2017-07-25 2021-11-23 Massachusetts Institute Of Technology In situ ATAC sequencing
WO2019046699A1 (en) * 2017-09-01 2019-03-07 Massachustetts Institute Of Technology NON-DETERGENT GPCR BIOELECTRONIC INTERFACES COUPLED TO THE 2D S-PROTEIN NETWORK, DEVICES AND METHODS OF USE THEREOF
US11173992B2 (en) 2017-12-28 2021-11-16 Legionarus, Llc Buoyancy garment
US11873374B2 (en) 2018-02-06 2024-01-16 Massachusetts Institute Of Technology Swellable and structurally homogenous hydrogels and methods of use thereof
WO2020013833A1 (en) 2018-07-13 2020-01-16 Massachusetts Institute Of Technology Dimethylacrylamide (dmaa) hydrogel for expansion microscopy (exm)
US11471112B2 (en) 2018-11-21 2022-10-18 Legionarius, Llc Mobile application for wearable device
USD905935S1 (en) 2019-02-20 2020-12-29 Legionarius, Llc Shirt with back pocket
US12478324B2 (en) 2019-02-20 2025-11-25 Legionarius, Llc Sensors for wearable devices
US12405193B2 (en) 2019-02-22 2025-09-02 Massachusetts Institute Of Technology Iterative direct expansion microscopy
US12265004B2 (en) 2019-11-05 2025-04-01 Massachusetts Institute Of Technology Membrane probes for expansion microscopy
WO2021113505A1 (en) 2019-12-05 2021-06-10 Massachusetts Institute Of Technology Method for preparing a specimen for expansion microscopy
WO2026021448A1 (zh) * 2024-07-22 2026-01-29 健达九州(北京)生物科技有限公司 一种M4Di变体以及其治疗癫痫的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5063245A (en) * 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5786203A (en) * 1994-06-14 1998-07-28 Neurocrine Biosciences, Inc. Isolated nucleic acid encoding corticotropin-releasing factor2 receptors
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US6353152B1 (en) * 1999-07-15 2002-03-05 Research Development Foundation Corticotropin releasing factor receptor 2 deficient mice and uses thereof
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
CA2576435A1 (en) 2004-08-09 2006-03-23 Research Development Foundation Determination of the 3d-structure of an extracellular domain of a b1 g-protein coupled receptor by nmr analysis

Also Published As

Publication number Publication date
EP1885746A2 (en) 2008-02-13
DK1885746T3 (da) 2012-03-26
US20070042954A1 (en) 2007-02-22
CA2597065A1 (en) 2006-08-17
CN101137668B (zh) 2011-08-17
RU2007133648A (ru) 2009-03-20
JP2008529500A (ja) 2008-08-07
KR20070112155A (ko) 2007-11-22
WO2006086402A2 (en) 2006-08-17
ATE540970T1 (de) 2012-01-15
JP4859248B2 (ja) 2012-01-25
WO2006086402A3 (en) 2006-12-14
AU2006212813A1 (en) 2006-08-17
CN101137668A (zh) 2008-03-05
US7507794B2 (en) 2009-03-24
RU2423378C2 (ru) 2011-07-10
US8258279B2 (en) 2012-09-04
EP1885746B1 (en) 2012-01-11
AU2006212813B2 (en) 2012-02-02
US20090117649A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
CA2597065C (en) Compositions and methods related to soluble g-protein coupled receptors (sgpcrs)
SG166090A1 (en) Il-13 binding agents
SG196835A1 (en) Human anti-b7rp1 neutralizing antibodies
DE602007006492D1 (de) Derivatisierung des granulozytenkoloniestimulierenden faktors
MXPA05007348A (es) Derivados de polimeros solubles en agua tiol-selectivos.
WO2006083275A3 (en) Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof
WO2009155324A3 (en) Pigf-1 assay and kits and components thereof
CY1114746T1 (el) Ποτα πρωτεϊνης που εχουν υποστει οξινιση και περιεχουν εναιωρουμενα σωματιδια και μεθοδοι παρασκευης τους
WO2007144893A3 (en) Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
GB0304068D0 (en) Substances
WO2006009734A8 (en) Gonadotropin releasing hormone receptor antagonists
NO20081298L (no) Peptider og forbindelser som binder til en reseptor
EA200600477A1 (ru) Пептиды и соединения, которые связываются с рецептором
Veevers et al. Central Antarctic provenance of Permian sandstones in Dronning Maud Land and the Karoo Basin: Integration of U–Pb and TDM ages and host-rock affinity from detrital zircons
EP1704853A3 (en) Water-in-silicone emulsion compositions
WO2005065015A3 (en) Neutralizing antibodies and methods of use thereof
TW200724159A (en) Stable emulsion composition
EA200702193A1 (ru) Гликозилирование белков
MX2007010220A (es) Peptidos para la deteccion de anticuerpo para el virus del sindrome respiratorio reproductivo porcino.
EA200601759A1 (ru) Композиции рамиприла
WO2004108887A3 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
WO2007067983A3 (en) Sulfotyrosine specific antibodies and uses therefor
WO2008063321A3 (en) Gpr81-ligand complexes and their preparation and use
WO2008100288A3 (en) High affinity ephb receptor binding compounds and methods of use thereof
BRPI0410252A (pt) materiais de revestimento de um componente termicamente curáveis, sua preparação e uso

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210831

MKLA Lapsed

Effective date: 20200210